Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor in atherogenic dyslipidaemic patients with abdominal obesity
NCT01271751Phase 2Completed
- Sponsor
- Genfit
- Start
- Jan 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in atherogenic dyslipidemia (AD) comparing GFT505 80mg with Matching placebo (2 arms). Primary endpoints: Serum Triglycerides at 28 days and Serum High Density Lipoprotein Cholesterol at 28 days. Started Jan 2009; status: completed.
02
Drugs
elafibranor
03
Conditions
atherogenic dyslipidemia (AD)
Beyond the preview
Go deeper on NCT01271751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271751.